GEM Study Links Leaky Gut to Crohn’s disease
- Stocks gain as dollar eases, oil gets a boost from OPEC+ deal
- Musk Failed to Convince Twitter (TWTR) to Lower the Deal Price - Reports
- Citi Says Buy US and UK Equities, Sees 18% Upside in Global Equities to End-2023
- Dollar wavers with ECB minutes and Friday's U.S. jobs data in focus
- Oil hovers near three-week highs after OPEC+ agrees to slash crude output
International project led by Crohn’s and Colitis Canada is getting us closer to preventing Crohn’s disease and ultimately, a cure
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Crohn’s and Colitis Canada is pleased to announce that the world-renowned Genetic, Environmental, Microbial (GEM) Project has led to a significant finding. Launched in 2008, the GEM Project is the world’s largest clinical study investigating the causes of Crohn’s disease. In this study of prospective development of Crohn’s, researchers have been monitoring thousands of healthy individuals who have a sibling or parent with the disease and are tracking their diet, immune function, intestinal barriers, microbiome, genetics, and environment. So far, 95 participants have been diagnosed with Crohn’s disease, a debilitating, chronic condition for which there is currently no cure. Fifty of the 95 participated in a recent gut barrier analysis.
“The project’s design was based on a simple question: why does one person develop Crohn’s disease instead of someone else?” says Dr. Croitoru, the lead investigator. “With over 10 years of data and technology that has evolved, we are able to perform analyses that we never dreamed of in 2008. No one else in the world has such a cohort of people, samples, and data to investigate the causes of Crohn’s disease. We have long focused on how to control the symptoms, and the inflammation. Here, we are asking how to cure the disease, and we now have intriguing data about the potential early triggers of Crohn’s,” adds Dr. Croitoru. The gut barrier analysis, Increased Intestinal Permeability is Associated with Later Development of Crohn’s Disease published in the AGA (American Gastroenterological Association) journal “Gastroenterology” sheds further light on these predictors.
The study assessed whether defects in the gut barrier function could be linked to a person’s future risk of developing Crohn’s disease. The lining of a person’s gut serves as a barrier separating gut microbes and the immune response. It has long been thought that a breakdown of this barrier (called “leaky gut”) could lead to the development of gut inflammation. Although healthy relatives of Crohn’s disease patients may have altered barrier function, this has never been shown to precede or lead to development of Crohn’s disease.
The study found that healthy first-degree relatives of Crohn’s disease patients, who eventually developed Crohn’s disease themselves, had abnormal LacMan ratios when enrolled in the study. Gut barrier integrity was measured using Lactulose Mannitol Ratio or LacMan ratio. Lactulose is a large sugar that normally does not cross the gut barrier. Higher levels of lactulose in the urine is suggestive of a leaky gut. This is the first report of pre-existing abnormal barrier function in a large study of healthy individuals followed over time for the development of Crohn’s disease demonstrating that the LacMan ratio can predict disease.
During this phase of the GEM Project, researchers are seeking to develop predictive tests that can identify individuals who will develop the disease, even before symptoms appear. Crohn’s and Colitis Canada is thankful toward their donors and to The Leona M. and Harry B. Helmsley Charitable Trust for believing in research like the GEM Project, and to the participants and researchers who make these advancements possible. “Crohn’s and Colitis Canada is proud to be driving world-renowned, game-changing Crohn’s and colitis research thanks to the passion and curiosity of Canadian researchers like Dr. Ken Croitoru and his team, combined with the generous support and patience of our donors,” says Mina Mawani, President and CEO of Crohn’s and Colitis Canada. “High-impact research like the GEM Project takes significant time and money, but the value of the research outcomes makes the investment worthwhile, as we find ways to prevent these devastating diseases,” she adds.
While the GEM Project focuses on Crohn’s disease, the research also feeds into the understanding of ulcerative colitis, a similar inflammatory bowel disease (IBD), which could lead to more targeted, and more effective, treatments.
To learn more about the GEM Project, visit crohnsandcolitis.ca/gem
About Crohn’s Disease and Ulcerative ColitisCrohn’s disease and ulcerative colitis – the two main forms of inflammatory bowel disease (IBD) – are autoimmune diseases that cause the body to attack healthy tissue, leading to the inflammation of all or part of the gastrointestinal tract. Symptoms include abdominal pain, cramping, fatigue, internal bleeding, and frequent and urgent bowel movements, in some cases over 20 times a day. Canada has some of the highest prevalence of Crohn’s and colitis in the world, with approximately 270,000 people diagnosed. One Canadian is newly diagnosed with Crohn’s or colitis every hour.
About Crohn’s and Colitis CanadaCrohn’s and Colitis Canada is on a relentless journey to find the cures for Crohn’s disease and ulcerative colitis and improve the lives of children and adults affected by these chronic diseases. We are the country’s largest volunteer-based organization with this mission and are one of the top two health charity funders of Crohn’s and colitis research in the world, investing over $130 million in research to date. We are transforming the lives of people affected by Crohn’s and colitis through research, patient programs, advocacy, and awareness. For more information, visit crohnsandcolitis.ca and follow us @getgutsycanada on Twitter, Facebook, and Instagram.
For more information, or to arrange interviews, please contact: Angie Specic Crohn’s and Colitis Canada [email protected]416-920-5035 x210
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Bank Plc - Form 8.5 (EPT/RI) - Shaftesbury PLC
- Dimensional Fund Advisors Ltd. : Form 8.3 - CAPITAL & COUNTIES PROPERTIES - Ordinary Shares
- Arhaus to Report Third Quarter 2022 Financial Results on November 10, 2022
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!